Ipragliflozin
| Code | Size | Price |
|---|
| AG-CR1-3546-M010 | 10 mg | £45.00 |
Quantity:
| AG-CR1-3546-M050 | 50 mg | £150.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short term: +4°C. Long term: -20°C
Documents
Further Information
Alternate Names/Synonyms:
ASP1941
Appearance:
White to off-white solid.
CAS:
761423-87-4
EClass:
32160000
Form (Short):
solid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.
Hazards:
H335
InChi:
InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1
InChiKey:
AHFWIQIYAXSLBA-RQXATKFSSA-N
Long Description:
Chemical. CAS: 761423-87-4. Formula: C21H21FO5S. MW: 404.5. Ipragliflozin is an orally active, highly potent sodium glucose co-transporter 2 (SGLT-2) inhibitor (IC50 = 7.4nM), selective over SGLT-1, 3, 4, 5 and 6. SGLT-2 is one subtype of SGLTs found almost exclusively in the proximal tubules of nephronic components in kidneys, playing a key role in the re-uptake of glucose in the proximal tubule of the kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE). Anti-diabetic and anti-obesity agent. Shown to improve glycemic control and reduce body weight, furthermore, lowering hypoglycemic risk and abdominal symptoms. SGLT-2 inhibitors are likely to improve beta-cell function and insulin sensitivity and restore glucose homeostasis. Attenuates non-alcoholic steatohepatitis (NASH) development.
MDL:
MFCD19443744
Molecular Formula:
C21H21FO5S
Molecular Weight:
404.5
Package Type:
Vial
Precautions:
P261, P304+P340
Product Description:
Ipragliflozin is an orally active, highly potent sodium glucose co-transporter 2 (SGLT-2) inhibitor (IC50 = 7.4nM), selective over SGLT-1, 3, 4, 5 and 6. SGLT-2 is one subtype of SGLTs found almost exclusively in the proximal tubules of nephronic components in kidneys, playing a key role in the re-uptake of glucose in the proximal tubule of the kidneys. Inhibition of SGLT-2 reduces blood glucose by blocking renal glucose reabsorption and thereby increasing urinary glucose excretion (UGE). Anti-diabetic and anti-obesity agent. Shown to improve glycemic control and reduce body weight, furthermore, lowering hypoglycemic risk and abdominal symptoms. SGLT-2 inhibitors are likely to improve beta-cell function and insulin sensitivity and restore glucose homeostasis. Attenuates non-alcoholic steatohepatitis (NASH) development.
Product Line Areas NEW:
Biochemicals, Immunology, Inflammation, Metabolism, Obesity
Product Type:
Chemical
Purity:
>98%
Signal word:
Warning
SMILES:
FC(C=CC([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)=C2)=C2CC3=CC4=CC=CC=C4S3
Solubility Chemicals:
Soluble in DMSO, DMF or ethanol (all 20mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20A°C.
References
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo: A. Tahara, et al.; Naunyn Schmiedebergs Arch. Pharmacol. 385, 423 (2012) | Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus: M. Imamura, et al.; Bioorg. Med. Chem. 20, 3263 (2012) | Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice: A. Tahara, et al.; Eur. J. Pharmacol. 715, 246 (2013) | Ameliorated pancreatic beta cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin: M. Takahara, et al.; Endocr. J. 62, 77 (2015) | Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus: T. Kawata, et al.; J. Clin. Med. Res. 9, 586 (2017) | In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor: T. Takasu, et al.; Biol. Pharm. Bull. 42, 507 (2019) | Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules: K. Hosokawa, et al.; Int. J. Mol. Sci. 26, 190 (2019) | SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation: S. Komatsu, et al.; Endocr. J. 67, 99 (2020) | Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model: A. Morishita, et al.; PLoS One 17, e0261310 (2022)